ALKERMES, INC.
🇺🇸United States
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02508506
- Locations
- 🇺🇸
Alkermes Investigational SIte, Orlando, Florida, United States
🇺🇸Alkermes Investigational Site, Minneapolis, Minnesota, United States
A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02504463
- Locations
- 🇺🇸
Alkermes Investigational Site, Austin, Texas, United States
A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 129
- Registration Number
- NCT02479308
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02452801
- Locations
- 🇺🇸
Alkermes Investigational Site, Orlando, Florida, United States
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02413281
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02320032
- Locations
- 🇺🇸
Alkermes Investigational Site, Dallas, Texas, United States
A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02272764
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 407
- Registration Number
- NCT02218008
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT02218021
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Phase 2
Completed
- Conditions
- Alcohol Use DisorderSchizophrenia
- Interventions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT02161718
- Locations
- 🇵🇱
Alkermes Investigational Site, Lublin, Poland
© Copyright 2025. All Rights Reserved by MedPath